A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Goodyear, Arizona +95 locations
Conditions: Neoplasms
Register for Updates
Molecular Detection of Advanced Neoplasia in Pancreatic Cysts
NCT03855800
Recruiting
Researchers are trying to find out whether new tests ("biomarkers") of blood, stool, pancreas cyst fluid, or pancreas juice can be used to diagnose malignant or pre-malignant changes in pancreas cysts.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/18/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pancreas Cyst
Register for Updates
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
NCT04500665
Recruiting
This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
06/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Chronic Kidney Diseases
Register for Updates
Virtual 1-Session Spanish "Empowered Relief" Group Intervention for Chronic Pain
NCT04546685
Recruiting
Empowered Relief (ER) is a 1-session pain relief skills intervention that is delivered in-person or online by certified clinicians to groups of patients with acute or chronic pain. Prior work in has shown ER efficacy for reducing chronic pain, pain-related distress, and other symptoms 6 months post-treatment. The purpose of this randomized trial is to conduct the first feasibility and early efficacy test of online Spanish ER delivered to Spanish-speaking adult patients with chronic pain. Partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: 1070 Arastradero Rd, Palo Alto, California
Conditions: Chronic Pain
Register for Updates
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
NCT04900298
Recruiting
The investigators hypothesize that the use of a personal hand hygiene system (SafeHavenTM) by anesthesia providers in the adult operating room, combined with a novel infectious pathogen tracking system (OR PathTrac) will decrease participant exposure to pathologic bacteria in the adult operating room.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/18/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Surgical Wound Infection, Cross Infection
Register for Updates
Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT
NCT05011149
Recruiting
Background: Among preterm infants, those born at a gestational age less than 26 weeks are considered the most vulnerable with a high risk of short- and long-term health problems that include chronic lung disease, brain bleeds, gut injury, kidney failure and death. Patent ductus arteriosus (PDA) is the most common heart condition with almost 70% preterm infants in this gestational age group being diagnosed with a PDA. Though many PDAs spontaneously resolve on their own, research suggests that if... Read More
Gender:
ALL
Ages:
72 hours and below
Trial Updated:
06/18/2024
Locations: Children's Hospital of Orange County, Orange, California +8 locations
Conditions: Patent Ductus Arteriosus After Premature Birth
Register for Updates
Multiple Sclerosis Falls Insight Track
NCT05837949
Recruiting
The purpose of this study is to develop an application: MS Falls Insight Track (MS FIT) which allows patients to log their falls and near falls, view their MS relevant data and responses to the clinic intake survey as well as communicate with their care team about falls and receive educational material on falls prevention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis
Register for Updates
Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice
NCT05877391
Recruiting
Older sexual and gender minority (SGM) patients are at risk for receiving inequitable end-of-life care; those with Alzheimer's disease and related dementias (ADRD) are at particularly high risk. Failure to collect and integrate sexual orientation and gender identity (SOGI) data to identify patients' informal support systems may have adverse health consequences for SGM older adults, particularly for those dependent on informal caregivers to provide in-home support and assist with activities of da... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Sexual and Gender Minorities, Hospice, Alzheimer's Disease and Related Dementias
Register for Updates
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
NCT06110572
Recruiting
This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation \[TBI\]) and higher dose radiation to known areas of cancer (hypofractionated radiation therapy \[H-RT\]) combined with atezolizumab and chemotherapy (carboplatin \& etoposide) in treating patients with small cell lung cancer that has spread to disease sites outside of the lung (extensive stage). Extensive stage disease has historically been treated with chem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Register for Updates
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
NCT06207370
Recruiting
This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen (A/A) that is recommended in the 2020 IDSA guideline on the diagnosis and management of babesiosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Babesiosis
Register for Updates
Cardiometabolic Consequences of the Loss of Ovarian Function
NCT06264882
Recruiting
The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function an... Read More
Gender:
FEMALE
Ages:
Between 20 years and 45 years
Trial Updated:
06/18/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Menopause, Estrogen Deficiency, Aging, Adiposity
Register for Updates
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY
NCT06358638
Recruiting
This multicenter prospective study seeks to determine if daratumumab given, prior to HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus, can prevent pure red blood cell aplasia with an acceptable safety profile in patients with anti-donor red blood cell antibodies, achieving an event-free survival similar to transplanted patients without such antibodies.
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
06/18/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sickle Cell Disease
Register for Updates